Access
Provider assessment
Quantity
Confirm with dispensing pharmacy
Evidence
No verified controlled trial of this finished cream

A cream accessed through a clinical service

Bounce Back sits in a different buying category from a serum placed directly into a retail basket. CoreAge Rx presents it as a compounded, provider-guided copper-peptide cream. The decision includes an online assessment, individual prescribing directions, a dispensing pharmacy and ongoing payment terms. Someone who wants help reviewing existing prescription skincare may value that process; someone who simply wants an additional moisturizer may prefer to compare a retail formula first.

The current product page describes a light cream for nighttime use. We have not applied or laboratory-tested it, so those texture descriptions remain the provider’s account. Photographs and the word recovery do not establish suitability for a fresh procedure site, broken skin or an undiagnosed rash.

What the ingredient summary actually tells us

The current product page lists copper peptide at 2%. It does not identify that ingredient unequivocally as GHK-Cu or supply a complete cream-base ingredient list. We therefore do not translate the headline into a verified amount of pure GHK-Cu, compare it mathematically with another peptide complex, or call the preparation twice as effective as a 1% product.

Request the exact peptide identity and full supplied formulation from the pharmacy before deciding around an allergy or ingredient avoidance. A marketing ingredient panel and an individual dispensing label have different jobs. Keep the latter as the reference for your own instructions, storage and beyond-use date.

Reading the monthly offer

The verified public starting price is $64.99 per month. The page advertises free delivery and no membership fee. A monthly price alone does not identify container volume, expected application quantity or whether the prescription offered after assessment matches the starting tier. We leave the price-per-milliliter field unavailable because a defensible denominator is missing.

Before paying, obtain the amount due now, what triggers a refill charge and how cancellation works before dispensing. Ask whether a consultation has a separate nonrefundable charge and how a clinician handles an unsuitable assessment. These are questions to resolve, rather than assumed additional fees.

Evidence should follow the finished preparation

Ingredient research can explain why copper peptides interest formulators. It cannot demonstrate a particular wrinkle reduction for this undisclosed finished base. We did not verify a published controlled trial of Bounce Back itself. CoreAge Rx’s featured placement is commercial and does not alter that evidence boundary.

A compounded prescription is also not an FDA-approved finished product. FDA explains that compounded drugs do not undergo the same premarket approval review as approved medicines. Provider involvement can support individualized decisions without turning cosmetic marketing into proof of clinical superiority.

Deciding whether this route fits

Bring the names of your cleanser, moisturizer, sunscreen, retinoid and exfoliants to the consultation. Ask whether Bounce Back replaces an existing step or adds one, and agree on the particular appearance or comfort goal you will reassess. A precise question about tolerability is more useful than asking whether every peptide is gentle.

The service is most understandable when the formula, total recurring payment and follow-up plan are clear together. If the pharmacy cannot clarify a relevant ingredient or quantity, postpone the comparison instead of filling the gap with another brand’s information.

Useful distinctions

  • Provider-guided access rather than a retail-only transaction
  • Public monthly starting price
  • Current page identifies a copper-peptide cream

Limitations to weigh

  • Full cream-base ingredients and exact peptide identity require clarification
  • Container volume not verified; no price-per-milliliter comparison
  • Finished-formula clinical superiority not established

Sources & further reading

Official pages and evidence consulted for this article. Checked October 11, 2026. Provider pages establish advertised terms; they do not independently establish effectiveness.

  1. CoreAge Rx: Bounce Back current product and plan Manufacturer
  2. FDA: Understanding the risks of compounded drugs Regulatory